KR20180070563A - 통증 치료용 조성물 및 방법 - Google Patents

통증 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20180070563A
KR20180070563A KR1020187008538A KR20187008538A KR20180070563A KR 20180070563 A KR20180070563 A KR 20180070563A KR 1020187008538 A KR1020187008538 A KR 1020187008538A KR 20187008538 A KR20187008538 A KR 20187008538A KR 20180070563 A KR20180070563 A KR 20180070563A
Authority
KR
South Korea
Prior art keywords
fusion protein
toxin
receptor
pain
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187008538A
Other languages
English (en)
Korean (ko)
Inventor
알. 존 콜리어
이삭 치우
브레들리 엘. 펜텔트
케이스 앨런 포스터
실파 팔런
사이 만 리우
Original Assignee
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
메사추세츠 인스티튜트 오브 테크놀로지
입센 파마 에스.에이.에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레지던트 앤드 펠로우즈 오브 하바드 칼리지, 메사추세츠 인스티튜트 오브 테크놀로지, 입센 파마 에스.에이.에스 filed Critical 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Publication of KR20180070563A publication Critical patent/KR20180070563A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020187008538A 2015-08-27 2016-08-26 통증 치료용 조성물 및 방법 Withdrawn KR20180070563A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210610P 2015-08-27 2015-08-27
US62/210,610 2015-08-27
PCT/US2016/049106 WO2017035508A1 (en) 2015-08-27 2016-08-26 Compositions and methods for treatment of pain

Publications (1)

Publication Number Publication Date
KR20180070563A true KR20180070563A (ko) 2018-06-26

Family

ID=58101095

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187008538A Withdrawn KR20180070563A (ko) 2015-08-27 2016-08-26 통증 치료용 조성물 및 방법
KR1020187008537A Withdrawn KR20180050679A (ko) 2015-08-27 2016-08-26 통증 치료용 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187008537A Withdrawn KR20180050679A (ko) 2015-08-27 2016-08-26 통증 치료용 조성물 및 방법

Country Status (11)

Country Link
US (4) US11753633B2 (cg-RX-API-DMAC10.html)
EP (2) EP3341391A4 (cg-RX-API-DMAC10.html)
JP (2) JP2018530315A (cg-RX-API-DMAC10.html)
KR (2) KR20180070563A (cg-RX-API-DMAC10.html)
CN (2) CN108350039A (cg-RX-API-DMAC10.html)
AU (2) AU2016312685A1 (cg-RX-API-DMAC10.html)
BR (2) BR112018003782A2 (cg-RX-API-DMAC10.html)
CA (2) CA2994560A1 (cg-RX-API-DMAC10.html)
EA (1) EA201890587A1 (cg-RX-API-DMAC10.html)
MX (1) MX2018002183A (cg-RX-API-DMAC10.html)
WO (2) WO2017035508A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080682A1 (ko) * 2022-10-12 2024-04-18 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354962A1 (en) * 2015-05-12 2022-11-10 The Trustees Of The University Of Pennsylvania Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
MX2018002183A (es) 2015-08-27 2018-05-28 Harvard College Composiciones y metodos para tratamiento del dolor.
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
CN112105379A (zh) * 2017-09-29 2020-12-18 儿童医学中心公司 神经毒素样毒素及其用途
BR112020006827A2 (pt) 2018-01-29 2020-10-06 Ipsen Biopharm Limited neurotoxinas botulínicas clivando snare não neuronal
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
CA3101481A1 (en) * 2018-05-30 2019-12-05 The Governing Council Of The University Of Toronto Methods and kits for identifying a protein associated with receptor-ligand interactions
US20210380700A1 (en) * 2018-07-06 2021-12-09 Abmax Biopharmaceuticals De-adcc/cdc functions of antibodies and their applications
MX2021001181A (es) 2018-07-31 2021-04-19 Snoretox Pty Ltd Neurotoxinas tetanicas pegiladas y tratamiento de la hipotonia.
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도
EP4093434A4 (en) * 2020-01-21 2024-06-26 Trustees of Dartmouth College Immunologically optimized botulinum toxin light chain variants
JP2023522534A (ja) * 2020-02-03 2023-05-31 プレマス バイオテック プライベート リミテッド 発現が困難なタンパク質を発現させるための、組換え発現プラットフォーム、構築物、および方法
US20230165812A1 (en) * 2020-02-27 2023-06-01 President And Fellows Of Harvard College Nociceptor neurons control cancer immunosurveillance
GB202104294D0 (en) * 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CN122520722A (zh) * 2024-03-26 2026-08-07 广州锡滔生物医药科技有限公司 一种多肽及其应用
WO2026076425A1 (en) 2024-10-04 2026-04-09 Biodrive, Inc. Oral biodelivery platform
CN122080238B (zh) * 2026-04-21 2026-07-31 成都锐翼生物科技有限公司 rBoNT重组蛋白及其前体及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
JP2000503004A (ja) 1995-12-13 2000-03-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ 化合物を細胞に輸送するための毒素ペプチドおよび／またはアフィニティハンドルの使用
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6767896B1 (en) 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
EP2267008B1 (en) 1999-08-25 2014-07-02 Allergan, Inc. Activatable recombinant neurotoxins
EP1214340B1 (en) 1999-09-24 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
JP2003533178A (ja) 1999-12-30 2003-11-11 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション Ｏ−スーパーファミリー・コノトキシンペプチド
JP2006507800A (ja) * 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
JP2009514545A (ja) 2005-11-08 2009-04-09 アテリス ラボラトリーズ μ−コノトキシンぺプチドおよびμ−コノトキシンぺプチドの局所麻酔薬としての使用
CA2601537A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
CA2865243A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014088928A1 (en) 2012-12-03 2014-06-12 President And Fellows Of Harvard College Methods for making targeted protein toxins by sortase-mediated protein ligation
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
MX2018002183A (es) 2015-08-27 2018-05-28 Harvard College Composiciones y metodos para tratamiento del dolor.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080682A1 (ko) * 2022-10-12 2024-04-18 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체
KR102728382B1 (ko) * 2022-10-12 2024-11-14 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체

Also Published As

Publication number Publication date
AU2016312685A1 (en) 2018-03-01
EP3341392A4 (en) 2019-01-23
US20180251740A1 (en) 2018-09-06
EP3341392A1 (en) 2018-07-04
US11104892B2 (en) 2021-08-31
AU2016310521A1 (en) 2018-03-01
WO2017035507A1 (en) 2017-03-02
JP2018525021A (ja) 2018-09-06
EP3341391A4 (en) 2019-03-06
JP2018530315A (ja) 2018-10-18
US10704035B2 (en) 2020-07-07
CN108350039A (zh) 2018-07-31
EA201890587A1 (ru) 2018-09-28
US11753633B2 (en) 2023-09-12
CA2994560A1 (en) 2017-03-02
EP3341391A1 (en) 2018-07-04
US20180244731A1 (en) 2018-08-30
CN108602861A (zh) 2018-09-28
BR112018003782A2 (pt) 2018-09-25
KR20180050679A (ko) 2018-05-15
CA2994729A1 (en) 2017-03-02
MX2018002183A (es) 2018-05-28
WO2017035508A1 (en) 2017-03-02
US20220033795A1 (en) 2022-02-03
BR112018003794A2 (pt) 2018-09-25
US20200362325A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
US11104892B2 (en) Compositions and methods for treatment of pain
TWI725963B (zh) 工程化之肉毒桿菌神經毒素
KR102617830B1 (ko) 양이온성 신경독소
US7514088B2 (en) Multivalent Clostridial toxin derivatives and methods of their use
US20240018196A1 (en) Topical compositions and uses
US20200255481A1 (en) Neurotoxin-like toxin and uses thereof
JP7100020B2 (ja) 操作されたボツリヌス神経毒素
MXPA00011148A (es) Proteina hibrida para la inhibicion de la desgranulacion de los mastocitos y su utilizacion..
TW201639876A (zh) 嵌合多肽
CA3228712A1 (en) Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
US20240216487A1 (en) Intramuscular compositions of botulinum neurotoxins
US20240158773A1 (en) Engineered botulinum neurotoxin a protease domain with improved efficacy
US20180298367A1 (en) Suppression of itch
HK1261168A1 (zh) 用於治疗疼痛的组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000